On August 1, 2025, we entered into an Equity Purchase Agreement (the "Equity Purchase Agreement") by and among Joby Aero, Inc., our wholly owned subsidiary, Blade Air Mobility, Inc. ("Seller"), Trinity Medical Intermediate II, Inc., ("NewCo"), and Blade Urban Air Mobility, Inc. (the "Blade Subsidiary" and together with Seller and NewCo, "Blade"), pursuant to which we will purchase Blade's passenger segment and operations. The Equity Purchase Agreement provides, among other things, that we will pay an aggregate amount up to $125 million as consideration, which includes (i) approximately $80 million in consideration payable upon closing of the acquisition, subject to certain adjustments as set forth in the Equity Purchase Agreement, (ii) up to $10 million in consideration that will be withheld by us for 18 months as partial security for, and subject to reduction in respect of, certain indemnification obligations under the Equity Purchase Agreement, (iii) up to $17.5 million in consideration that will become payable, if at all, subject to the achievement of certain EBITDA milestones by the acquired operations during the 12-month period following the closing of the acquisition and (iv) up to $17.5 million in consideration that will become payable, if at all, subject to our retention of certain key personnel of the acquired operations during the 18-month period following the closing of the acquisition. All or any portion of such payment obligations may be paid, at our election, in cash or in shares of our common stock, with any such common stock issued at a per share price equal to the average of the daily volume-weighted average sales price per share on the New York Stock Exchange, for each of the ten (10) trading days ending on the trading day preceding the date on which we become obligated to make the applicable payment. Because the price per share for any such issuance of shares of our common stock is based on the future trading prices of our common stock, we are currently unable to determine the aggregate number of shares that may be issued pursuant to the Equity Purchase Agreement; however, any such issuance of shares of our common stock would be subject to applicable rules and regulations, including the limitations set forth in the Section 312.03 of the New York Stock Exchange Listed Company Manual.
The closing of the acquisition and the obligations of the parties are subject to the satisfaction or waiver of a number of customary conditions, including, among others, the entry into an asset transfer agreement and separation of Blade's passenger segment from its medical transport segment. The asset transfer agreement and other documentation to be entered into in connection with the closing conditions are subject to the parties negotiating and entering into definitive agreements and the conditions included within the applicable definitive documents.
We may experience delays and difficulties in satisfying the conditions for closing, and cannot guarantee that closing will take place on the timeline currently anticipated or at all. Some of the conditions to closing are outside of our control and it is possible that not all of the closing conditions to acquisition will be satisfied. In addition, certain closing conditions require us and Blade to successfully negotiate and enter into an asset transfer agreement and other documentation. The final terms of such documents have not yet been agreed upon, and the negotiation and execution of such agreements may take longer than expected or may not be possible to accomplish on terms acceptable to us, or at all. No assurance can be given that any agreement we may reach will achieve our goals or be on terms that prove to be economically or strategically beneficial to us. Such adverse developments, including any failure to close, could adversely impact our business, financial condition, results of operations and liquidity.